Implications for the monitoring of patients with multiple myeloma undergoing treatment with the anti-CD38 monoclonal daratumumab

Ann Clin Biochem. 2020 Mar;57(2):178-181. doi: 10.1177/0004563219894354. Epub 2019 Dec 27.

Authors

Sally Thirkettle¹, Joanne Russell¹, Sarah Wilson¹, Tasneem Ganijee², Samar Kulkarni², Jim Cavet^{2

3}, Phillip J Monaghan^{1

4}

Affiliations

¹ The Christie Pathology Partnership, The Christie NHS Foundation Trust, Manchester, UK.
² Department of Haematology, The Christie NHS Foundation Trust, Manchester, UK.
³ Department of Medical Science, School of Biology, University of Manchester, Manchester, UK.
⁴ Faculty of Medical and Human Sciences, Institute of Inflammation and Repair, University of Manchester, Manchester, UK.

PMID: 31791138
DOI: 10.1177/0004563219894354

No abstract available

Keywords: Multiple myeloma; daratumumab; novel immunotherapies; serum protein electrophoresis.

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Artifacts
Blood Protein Electrophoresis / methods*
Humans
Immunoglobulin gamma-Chains / analysis
Immunoglobulin gamma-Chains / blood*
Immunoglobulin kappa-Chains / blood*
Multiple Myeloma / drug therapy*
Paraproteins / analysis*
Retrospective Studies

Substances

Antibodies, Monoclonal
Immunoglobulin gamma-Chains
Immunoglobulin kappa-Chains
Paraproteins
daratumumab